Yu AP - Search Results

1

Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis.

Chen L, Guérin A, Xie J, Wu EQ, Yu AP, Ericson SG, Jabbour E. Chen L, et al. Among authors: yu ap. Curr Med Res Opin. 2012 Nov;28(11):1831-9. doi: 10.1185/03007995.2012.741577. Epub 2012 Nov 5. Curr Med Res Opin. 2012. PMID: 23127201

2

Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement.

Chang J, Yang W, Fellers T, Kahler KH, Orloff J, Xie J, Tsaneva M, Yu AP, Wu EQ. Chang J, et al. Among authors: yu ap. Curr Med Res Opin. 2010 Sep;26(9):2203-12. doi: 10.1185/03007995.2010.500883. Curr Med Res Opin. 2010. PMID: 20673201

3

Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.

Wu EQ, Guerin A, Yu AP, Bollu VK, Guo A, Griffin JD. Wu EQ, et al. Among authors: yu ap. Curr Med Res Opin. 2010 Dec;26(12):2861-9. doi: 10.1185/03007995.2010.533648. Epub 2010 Nov 9. Curr Med Res Opin. 2010. PMID: 21062136

4

Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data.

Yu AP, Wu EQ, Birnbaum HG, Emani S, Fay M, Pohl G, Wintle M, Yang E, Oglesby A. Yu AP, et al. Curr Med Res Opin. 2007 Sep;23(9):2157-69. doi: 10.1185/0300799007X219544. Curr Med Res Opin. 2007. PMID: 17669232 Review.

5

Economic burden of psoriasis compared to the general population and stratified by disease severity.

Yu AP, Tang J, Xie J, Wu EQ, Gupta SR, Bao Y, Mulani PM. Yu AP, et al. Curr Med Res Opin. 2009 Oct;25(10):2429-38. doi: 10.1185/03007990903185557. Curr Med Res Opin. 2009. PMID: 19663687

6

Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus.

Pandya BJ, Bron M, McCall T, Yu AP, Chen KS, Mattson ME, Wu EQ. Pandya BJ, et al. Among authors: yu ap. Curr Med Res Opin. 2011 Jan;27(1):189-95. doi: 10.1185/03007995.2010.536755. Epub 2010 Dec 9. Curr Med Res Opin. 2011. PMID: 21142610

7

Copayment level, treatment persistence, and healthcare utilization in hypertension patients treated with single-pill combination therapy.

Yang W, Kahler KH, Fellers T, Orloff J, Chang J, Bensimon AG, Wu EQ, Fan CP, Yu AP. Yang W, et al. Among authors: yu ap. J Med Econ. 2011;14(3):267-78. doi: 10.3111/13696998.2011.570401. Epub 2011 Mar 30. J Med Econ. 2011. PMID: 21446895 Free article.

8

Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension.

Signorovitch J, Zhang J, Wu EQ, Latremouille-Viau D, Yu AP, Dastani HB, Kahler KH. Signorovitch J, et al. Among authors: yu ap. Curr Med Res Opin. 2010 Apr;26(4):849-60. doi: 10.1185/03007991003613910. Curr Med Res Opin. 2010. PMID: 20141381

9

The costs of Crohn's disease in the United States and other Western countries: a systematic review.

Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J. Yu AP, et al. Curr Med Res Opin. 2008 Feb;24(2):319-28. doi: 10.1185/030079908x260790. Curr Med Res Opin. 2008. PMID: 18067689 Review.

10

Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population.

Wu EQ, Feldman SR, Chen L, Kaltenboeck A, Yu AP, Gupta SR, Laitinen D, Willian MK. Wu EQ, et al. Among authors: yu ap. Curr Med Res Opin. 2008 Dec;24(12):3493-501. doi: 10.1185/03007990802551057. Curr Med Res Opin. 2008. PMID: 19032131

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

130 results

Search Page

Filters